Filing Details
- Accession Number:
- 0001562180-22-006788
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-09-21 16:18:27
- Reporting Period:
- 2022-09-19
- Accepted Time:
- 2022-09-21 16:18:27
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1395937 | Syndax Pharmaceuticals Inc | SNDX | Pharmaceutical Preparations (2834) | 320162505 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1654430 | Briggs Morrison | C/O Syndax Pharmaceuticals, Inc. 35 Gatehouse Drive, Building D, Floor 3 Waltham MA 02451 | President, Head Of R&D | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-09-19 | 114,339 | $10.90 | 132,175 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-09-19 | 114,339 | $23.03 | 17,836 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2022-09-20 | 59,649 | $10.90 | 77,485 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-09-20 | 59,649 | $23.25 | 17,836 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (Right to buy) | Disposition | 2022-09-19 | 114,339 | $0.00 | 114,339 | $10.90 |
Common Stock | Stock Options (Right to buy) | Disposition | 2022-09-20 | 59,649 | $0.00 | 59,649 | $10.90 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2025-09-09 | No | 4 | M | Direct | |
0 | 2025-09-09 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 774,958 options to purchase shares of common stock that are vested and immediately exercisable and a total of 370,042 options to purchase shares of common stock that have not yet vested.
- The sale prices ranged from $22.50 to $23.35
- The sale prices ranged from $22.60 to $23.75
- This option is fully vested.